Frequently Asked Questions About RSVpreF (Abrysvo) Vaccine for Pregnant People

Avoid potential vaccination errors –
Pregnant people should ONLY receive Pfizer RSVpreF (ABRYSVO) vaccine.

RSVpreF (Abrysvo) vaccine is the ONLY Respiratory Syncytial Virus (RSV) vaccine approved for use during pregnancy to protect infants from RSV-associated lower respiratory tract infection (LRTI). The vaccine should be administered during weeks 32 through 36 of pregnancy (i.e., 32 weeks 0 days through 36 weeks 6 days). In most of the continental United States, the vaccine should be administered from September through January.

To prevent RSV-associated LRTI in infants, CDC recommends either

  • Administering RSVpreF (Abrysvo) vaccine to the pregnant person

Most infants will not need protection from both products.

RSVpreF (Abrysvo) Vaccine Indication, Dosage and Schedule

Timing of RSVpreF (Abrysvo) Vaccination During Pregnancy

Vaccination Errors

RSVpreF (Abrysvo) Vaccine and RSV Infection

Adverse Events After RSVpreF (Abrysvo) Vaccination